#BEGIN_DRUGCARD DB08434

# AHFS_Codes:
Not Available

# ATC_Codes:
Not Available

# Absorption:
Not Available

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Not Available

# CAS_Registry_Number:
Not Available

# ChEBI_ID:
Not Available

# Chemical_Formula:
C12H14NO7P

# Chemical_IUPAC_Name:
(1R,2R,3S)-2-(methylcarbamoyl)-3-[4-(phosphonooxy)phenyl]cyclopropane-1-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2010-09-15 15:31:50 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Not Available

# Dosage_Forms:
Not Available

# Drug_Category:
Not Available

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Experimental
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
Not Available

# Experimental_Logs:
Not Available

# Experimental_Water_Solubility:
Not Available

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
2-METHYLCARBAMOYL-3-(4-PHOSPHONOOXY-PHENYL)-CYCLOPROPANECARBOXYLIC ACID

# HET_ID:
PTC

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C12H14NO7P/c1-13-11(14)9-8(10(9)12(15)16)6-2-4-7(5-3-6)20-21(17,18)19/h2-5,8-10H,1H3,(H,13,14)(H,15,16)(H2,17,18,19)/t8-,9+,10+/m0/s1

# InChI_Key:
InChIKey=GIIUHKRUTUSHAB-IVZWLZJFSA-N

# Indication:
Not Available

# KEGG_Compound_ID:
Not Available

# KEGG_Drug_ID:
Not Available

# LIMS_Drug_ID:
8440

# Mechanism_Of_Action:
Not Available

# Melting_Point:
Not Available

# Molecular_Weight_Avg:
315.2158

# Molecular_Weight_Mono:
315.050788319

# Organisms_Affected:
Not Available

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
Not Available

# Pharmacology:
Not Available

# Predicted_LogP_Hydrophobicity:
-0.33

# Predicted_LogS:
-2.5

# Predicted_Water_Solubility:
8.90e-01 g/l

# Primary_Accession_No:
DB08434

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5289221

# PubChem_Substance_ID:
99444905

# RxList_Link:
Not Available

# Salts:
Not Available

# Secondary_Accession_No:
Not Available

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
[H][C@]1(C(O)=O)[C@]([H])(C(=O)NC)[C@]1([H])C1=CC=C(OP(O)(O)=O)C=C1

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:26:50 -0700

# Wikipedia_Link:
Not Available

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
10592235	Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.

# Drug_Target_1_Essentiality:
Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
L29199

# Drug_Target_1_GenBank_ID_Protein:
459676

# Drug_Target_1_GeneCard_ID:
V-SRC

# Drug_Target_1_Gene_Name:
V-SRC

# Drug_Target_1_Gene_Sequence:
>1581 bp
ATGGGGAGTAGCAAGAGCAAGCCTAAGGACCCCAGCCAGCGCCGGCGCAGCCTGGAGCCA
CCCGACAGCACCCACCACGGGGGATTCCCAGCCTCGCAGACCCCCAACAAGACAGCAGCC
CCCGACACGCACCGCACCCCCAGCCGCTCCTTCGGGACCGTGGCCACCGAGCCCAAGCTC
TTCGGGGGCTTCAACACTTCTGACACCGTTACGTCGCCGCAGCGTGCCGGGGCACTGGCT
GGCGGCGTCACCACTTTCGTGGCTCTCTACGACTACGAGTCCTGGATTGAAACGGACTTG
TCCTTCAAGAAAGGAGAACGGCTGCAGATTGTCAACAACACGGAAGGTAACTGGTGGCTG
GCTCATTCCCTCACTACAGGACAGACGGGCTACATCCCCAGTAACTATGTCGCGCCCTCA
GACTCCATCCAGGCTGAAGAGTGGTACTTTGGGAAGATCACTCGTCGGGAGTCCGAGCGG
CTGCTGCTCAACCCCGAAAACCCCCGGGGAACCTTCTTGGTCCGGGAGAGCGAGACGACA
AAAGGTGCCTATTGCCTCTCCGTTTCTGACTTTGACAACGCCAAGGGGCTCAATGTGAAG
CACTACAAGATCCGCAAGCTGGACAGCGGCGGCTTCTACATCACCTCACGCACACAGTTC
AGCAGCCTGCAGCAGCTGGTGGCCTACTACTCCAAACATGCTGATGGCTTGTGCCACCGC
CTGACCAACGTCTGCCCCACGTCCAAGCCCCAGACCCAGGGACTCGCCAAGGACGCGTGG
GAAATCCCCCGGGAGTCGCTGCGGCTGGAGGTGAAGCTGGGGCAGGGCTGCTTTGGAGAG
GTCTGGATGGGGACCTGGAACGGCACCACCAGAGTGGCCATAAAGACTCTGAAGCCCGGC
ACCATGTCCCCGGAGGCCTTCCTGCAGGAAGCCCAAGTGATGAAGAAGCTCCGGCATGAG
AAGCTGGTTCAACTGTACGCAGTGGTGTCGGAAGAGCCCATCTACATCGTCATTGAGTAC
ATGAGCAAGGGGAGCCTCCTGGATTTCCTGAAGGGAGAGATGGGCAAGTACCTGCGGCTG
CCACAGCTCGTTGATATGGCTGCTCAGATTGCATCCGGCATGGCCTATGTGGAGAGGATG
AACTACGTGCACCGAGACCTGCGGGCGGCCAACATCCTGGTGGGGGAGAACCTGGTGTGC
AAGGTGGCTGACTTTGGGCTGGCACGCCTCATCGAGGACAACGAGTACACAGCACGGCAA
GGTGCCAAGTTCCCCATCAAGTGGACAGCCCCCGAGGCAGCCCTCTATGGCCGGTTCACC
ATCAAGTCGGATGTCTGGTCCTTCGGCATCCTGCTGACTGAGCTGACCACCAAGGGCCGG
GTGCCATACCCAGGGATGGGCAACGGGGAGGTGCTGGACCGGGTGGAGAGGGGCTACCGC
ATGCCCTGCCCGCCCGAGTGCCCCGAGTCGCTGCATGACCTTATGTGCCAGTGCTGGCGG
AGGGACCCTGAGGAGCGGCCCACTTTCGAGTACCTGCAGGCCCAGCTGCTCCCTGCTTGT
GTGTTGGAGGTCGCTGAGTAG

# Drug_Target_1_General_Function:
Involved in ATP binding

# Drug_Target_1_General_References:
11782172	Davidson JP, Lubman O, Rose T, Waksman G, Martin SF: Calorimetric and structural studies of 1,2,3-trisubstituted cyclopropanes as conformationally constrained peptide inhibitors of Src SH2 domain binding. J Am Chem Soc. 2002 Jan 16;124(2):205-15.
11851339	Lubman OY, Waksman G: Dissection of the energetic coupling across the Src SH2 domain-tyrosyl phosphopeptide interface. J Mol Biol. 2002 Feb 15;316(2):291-304.
12706723	Lubman OY, Waksman G: Structural and thermodynamic basis for the interaction of the Src SH2 domain with the activated form of the PDGF beta-receptor. J Mol Biol. 2003 May 2;328(3):655-68.
1379696	Waksman G, Kominos D, Robertson SC, Pant N, Baltimore D, Birge RB, Cowburn D, Hanafusa H, Mayer BJ, Overduin M, Resh MD, Rios CB, Silverman L, Kuriyan J: Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature. 1992 Aug 20;358(6388):646-53.
6253794	Czernilofsky AP, Levinson AD, Varmus HE, Bishop JM, Tischer E, Goodman HM: Nucleotide sequence of an avian sarcoma virus oncogene (src) and proposed amino acid sequence for gene product. Nature. 1980 Sep 18;287(5779):198-203.
6264320	Neil JC, Ghysdael J, Vogt PK, Smart JE: Homologous tyrosine phosphorylation sites in transformation-specific gene products of distinct avian sarcoma viruses. Nature. 1981 Jun 25;291(5817):675-7.
6298633	Czernilofsky AP, Levinson AD, Varmus HE, Bishop JM, Tischer E, Goodman H: Corrections to the nucleotide sequence of the src gene of Rous sarcoma virus. Nature. 1983 Feb 24;301(5902):736-8.
6299580	Takeya T, Hanafusa H: Structure and sequence of the cellular gene homologous to the RSV src gene and the mechanism for generating the transforming virus. Cell. 1983 Mar;32(3):881-90.
7680960	Waksman G, Shoelson SE, Pant N, Cowburn D, Kuriyan J: Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell. 1993 Mar 12;72(5):779-90.
9371236	Plummer MS, Holland DR, Shahripour A, Lunney EA, Fergus JH, Marks JS, McConnell P, Mueller WT, Sawyer TK: Design, synthesis, and cocrystal structure of a nonpeptide Src SH2 domain ligand. J Med Chem. 1997 Nov 7;40(23):3719-25.

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
6830

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
58877.5

# Drug_Target_1_Name:
Tyrosine-protein kinase transforming protein Src

# Drug_Target_1_Number_of_Residues:
526

# Drug_Target_1_PDB_ID:
2PTK

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
PF00017	SH2
PF00018	SH3_1
PF07714	Pkinase_Tyr

# Drug_Target_1_Protein_Sequence:
>Tyrosine-protein kinase transforming protein Src
MGSSKSKPKDPSQRRCSLEPPDSTHHGGFPASQTPNKTAAPDTHRTPSRSFGTVATEPKL
FGGFNTSDTVTSPQRAGALAGGVTTFVALYDYESRTETDLSFKKGERLQIVNNTEGDWWL
AHSLTTGQTGYIPSNYVAPSDSIQAEEWYFGKITRRESERLLLNPENPRGTFLVRESETT
KGAYCLSVSDFDNAKGLNVKHYKIRKLDSGGFYITSRTQFSSLQQLVAYYSKHADGLCHR
LTNVCPTSKPQTQGLAKDAWEIPRESLRLEVKLGQGCFGEVWMGTWNGTTRVAIKTLKPG
TMSPEAFLQEAQVMKKLRHEKLVQLYAVVSEEPIYIVTEYMSKGSLLDFLKGEMGKYLRL
PQLVDMAAQIASGMAYVERMNYVHRDLRAANILVGENLVCKVADFGLARLIEDNEYTARQ
GAKFPIKWTAPEAALYGRFTIKSDVWSFGILLTELTTKGRVPYPGMGNGEVLDRVERGYR
MPCPPECPESLHDLMCQCWRRDPEERPTFEYLQAQLLPACVLEVAE

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
None

# Drug_Target_1_Specific_Function:
This phosphoprotein, required for both the initiation and the maintenance of neoplastic transformation, is a protein kinase that catalyzes the phosphorylation of tyrosine residues in vitro

# Drug_Target_1_SwissProt_ID:
P00524

# Drug_Target_1_SwissProt_Name:
SRC_RSVSA

# Drug_Target_1_Synonyms:
p60-Src
pp60v-src
v-Src

# Drug_Target_1_Theoretical_pI:
7.87

# Drug_Target_1_Transmembrane_Regions:
None

#END_DRUGCARD DB08434
